SanBio
Tokyo
About SanBio
SanBio is a regenerative medicine company with cell-based products in various stages of research, development, and clinical trials. Its proprietary cell-based product, SB623, is currently in a Phase 2b clinical trial for treatment of chronic motor impairments resulting from stroke with its joint development partner, Sumitomo Dainippon Pharma Co., Ltd., in the United States and Canada. SanBio is also implementing a global Phase 2 clinical trial in the United States and Japan using SB623 for treatment of motor impairment resulting from traumatic brain injury.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $48.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jan 2020)
- Ticker: tyo:4592
- Website: sanbio.com
- Phone: +81 03-6264-348
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical
Canonical: https://fsome.com/organization/sanbio-168116 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.